Research
Hormonal
Prolonging the nightly fasting interval (≥11-13 hours) is associated with reduced odds of elevated HbA1c, lower inflammatory markers, and reduced breast cancer recurrence risk.
Aim for at least 13 hours of fasting between dinner and breakfast. This simple timing strategy is associated with lower inflammation and potentially better long-term health outcomes, including reduced cancer recurrence risk.
GoodSupportsHIGH confidence
Our prospective data analysis indicated that cancer survivors who fasted <13 hours per night during 7 years of follow up had an increased risk of recurrence (HR, 1.36; 95% CI, 1.05 to 1.76).
Why this rating
Large prospective cohort studies with significant hazard ratios, but observational design limits causal inference.
Source
Metabolic Effects of Intermittent Fasting
Ruth E. Patterson et al. · Annual Review of Nutrition · 2017
DOI 10.1146/annurev-nutr-071816-064634
narrative_reviewCited 800×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Time-restricted feeding (TRF) that aligns food intake with circadian rhythms (e.g., restricting eating to 8-12 hours during the day) improves metabolic health, including weight loss, insulin sensitivity, and lipid profiles, independent of caloric restriction.Moderate
- Alternate-day fasting (ADF) and modified fasting (e.g., 5:2 diet) result in weight loss comparable to continuous energy restriction, with mixed effects on metabolic biomarkers.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →